Our general aim is to investigate whether messenger RNA (mRNA) and/or microRNA (miRNA) expression profiles in white blood cells, predict metformin monotherapy efficacy in patients with type 2 diabetes.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Metformin, pills, 850 mg three times a day for three months
Casa Sollievo Della Sofferenza IRCCS
San Giovanni Rotondo, Foggia, Italy
Fasting glucose change after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells
Changes in fasting glucose levels will be used to evaluate if metformin monotherapy efficacy in type 2 diabetic patients is predicted by mRNA and/or miRNA expression profiles. Please note that metformin major effect is to decrease hepatic glucose output and, therefore, to lower fasting plasma glucose which is, in fact, the clinical outcome used in this study. Finally, because of a very short wash-out period (i.e. 5 days) we will not be able to use HbA1c which will be inevitably conditioned by previous oral hypoglicemic therapy.
Time frame: Baseline and after three months of metfomin therapy
Change in fasting insulin levels after metformin treatment in respect to mRNA and miRNA expression profiles in white blood cells
Time frame: Baseline and after three months of metfomin therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.